Horizon Therapeutics Plc

HZNP NASDAQ
23.46
0.00
0.00%
Opening 14:34 07/15 EDT
Open
23.37
Prev Close
23.46
High
23.46
Low
22.90
Volume
529.93K
Avg Vol (3M)
1.87M
52 Week High
29.44
52 Week Low
16.56
% Turnover
0.29%
Market Cap
4.34B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Horizon Therapeutics Plc HZNP stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Horizon Therapeutics PLC, formerly Horizon Pharma Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
MORE >

Recently

Name
Price
%Change